Ana Svensson

Dr. Ana Svensson is the Vice President of Clinical, Medical, and Regulatory Affairs at Novo Nordisk Oceania. She has been instrumental in advocating for broader access to GLP-1 therapies for obesity in Australia, emphasizing the need for affordability and equity in treatment options. Svensson has played a key role in the company's efforts to secure a listing for Wegovy on the Pharmaceutical Benefits Scheme (PBS) to improve access to obesity treatments for Australians.